<DOC>
	<DOCNO>NCT00103103</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , fluorouracil leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together fluorouracil leucovorin may kill tumor cell . PURPOSE : This phase II trial study well give bortezomib together fluorouracil leucovorin work treat patient metastatic unresectable stomach cancer .</brief_summary>
	<brief_title>Bortezomib , Fluorouracil , Leucovorin Treating Patients With Metastatic Unresectable Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response patient previously treat metastatic unresectable gastric gastroesophageal junction adenocarcinoma treat bortezomib , fluorouracil , leucovorin calcium . Secondary - Determine time progression overall survival patient treat regimen . - Determine toxic effect regimen patient . OUTLINE : This non-randomized , multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 8 , 15 . One hour completion bortezomib , patient receive leucovorin calcium IV fluorouracil IV follow fluorouracil IV continuously 46 hour day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow survival . PROJECTED ACCRUAL : A total 12-37 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis gastric gastroesophageal junction adenocarcinoma Metastatic unresectable disease Progressive disease receive 1 prior chemotherapy regimen metastatic disease comprise 1 follow : Fluorouracil Cisplatin irinotecan Capecitabine Taxanes Measurable disease No esophageal cancer No brain metastasis PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No acute ischemia EKG No significant conduction abnormality EKG , include either follow : Bifasicular block , define leave anterior hemiblock presence right bundle branch block Second third degree atrioventricular block No history cardiac cerebrovascular disease due hypotension tachycardia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , , 6 month study participation No ongoing active infection No uncontrolled illness No peripheral neuropathy ≥ grade 2 within past 2 week No allergy boron mannitol PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior immunotherapy Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery More 2 week since prior major surgery Other No concurrent highly active antiretroviral therapy HIVpositive patient No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>